HDAC Inhibitor Modulation of Proteotoxicity as a Therapeutic Approach in Cancer

Advances in Cancer Research

Volumn 116, Issue , 2012, Pages 131-163

  McConkey, David J ^a   White, Matthew ^a   Yan, Wudan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; BORTEZOMIB; CARFILZOMIB; ENTINOSTAT; GLUCOSE REGULATED PROTEIN 78; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; HEAT SHOCK COGNATE PROTEIN 70; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LONTUCIREV; MAMMALIAN TARGET OF RAPAMYCIN; ONCOLYTIC VIRUS; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEASOME; PROTEIN KINASE B; QUERCETIN; REACTIVE OXYGEN METABOLITE; SALINOSPORAMIDE A; TANESPIMYCIN; TRIPTOLIDE; UBIQUITIN; VORINOSTAT;

AGGRESOME; ARTICLE; AUTOPHAGY; CANCER CELL; CANCER THERAPY; CELL DEATH; CELL KILLING; CELL PROTECTION; CHROMATIN; CYTOTOXICITY; DEGENERATIVE DISEASE; DISEASE COURSE; ENDOPLASMIC RETICULUM STRESS; HEMATOLOGIC MALIGNANCY; MEDICAL DOCUMENTATION; MEDICAL LITERATURE; MULTIPLE MYELOMA; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN FOLDING; PROTEIN QUALITY; TUMOR CELL;

EID: 84867837864     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-394387-3.00004-5     Document Type: Chapter

References (161)

1. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004, 5(5):417-421. [Review].
2. Agarwal S., Roy S., Ray A., Mazumder S., Bhattacharya S. Arsenic trioxide and lead acetate induce apoptosis in adult rat hepatic stem cells. Cell Biology and Toxicology 2009, 25:403-413.
3. Ahn S.G., Kim S.A., Yoon J.H., Vacratsis P. Heat-shock cognate 70 is required for the activation of heat-shock factor 1 in mammalian cells. The Biochemical Journal 2005, 392(Pt 1):145-152.
4. Bali P., Pranpat M., Bradner J., Balasis M., Fiskus W., Guo F., et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: A novel basis for antileukemia activity of histone deacetylase inhibitors. The Journal of Biological Chemistry 2005, 280(29):26729-26734.
5. Basso A.D., Solit D.B., Munster P.N., Rosen N. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 2002, 21:1159-1166.
6. Bays N.W., Gardner R.G., Seelig L.P., Joazeiro C.A., Hampton R.Y. Hrd1p/Der3p is a membrane-anchored ubiquitin ligase required for ER-associated degradation. Nature Cell Biology 2001, 3(1):24-29. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
7. Bennett E.J., Bence N.F., Jayakumar R., Kopito R.R. Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. Molecular Cell 2005, 17(3):351-365. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
8. Bennett E.J., Shaler T.A., Woodman B., Ryu K.Y., Zaitseva T.S., Becker C.H., et al. Global changes to the ubiquitin system in Huntington's disease. Nature 2007, 448(7154):704-708. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
9. Bertolotti A., Zhang Y., Hendershot L.M., Harding H.P., Ron D. Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. Nature Cell Biology 2000, 2(6):326-332. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
10. Bi M., Naczki C., Koritzinsky M., Fels D., Blais J., Hu N., et al. ER stress-regulated translation increases tolerance to extreme hypoxia and promotes tumor growth. The EMBO Journal 2005, 24(19):3470-3481.
11. Blais J.D., Filipenko V., Bi M., Harding H.P., Ron D., Koumenis C., et al. Activating transcription factor 4 is translationally regulated by hypoxic stress. Molecular and Cellular Biology 2004, 24(17):7469-7482.
12. Brewer J.W., Diehl J.A. PERK mediates cell-cycle exit during the mammalian unfolded protein response. Proceedings of the National Academy of Sciences of the United States of America 2000, 97(23):12625-12630.
13. Burbulla L.F., Schelling C., Kato H., Rapaport D., Woitalla D., Schiesling C., et al. Dissecting the role of the mitochondrial chaperone mortalin in Parkinson's disease: Functional impact of disease-related variants on mitochondrial homeostasis. Human Molecular Genetics 2010, 19(22):4437-4452.
14. Chauhan D., Hideshima T., Anderson K.C. A novel proteasome inhibitor NPI-0052 as an anticancer therapy. British Journal of Cancer 2006, 95(8):961-965. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review].
15. Chen J.J., Throop M.S., Gehrke L., Kuo I., Pal J.K., Brodsky M., et al. Cloning of the cDNA of the heme-regulated eukaryotic initiation factor 2 alpha (eIF-2 alpha) kinase of rabbit reticulocytes: Homology to yeast GCN2 protein kinase and human double-stranded-RNA-dependent eIF-2 alpha kinase. Proceedings of the National Academy of Sciences of the United States of America 1991, 88(17):7729-7733.
16. Chin L.S., Olzmann J.A., Li L. Parkin-mediated ubiquitin signalling in aggresome formation and autophagy. Biochemical Society Transactions 2010, 38(Pt 1):144-149. [Research Support, N.I.H., Extramural Review].
17. Connell P., Ballinger C.A., Jiang J., Wu Y., Thompson L.J., Hohfeld J., et al. The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nature Cell Biology 2001, 3(1):93-96. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
18. Cox J.S., Shamu C.E., Walter P. Transcriptional induction of genes encoding endoplasmic reticulum resident proteins requires a transmembrane protein kinase. Cell 1993, 73(6):1197-1206.
19. Cusack J.C., Liu R., Baldwin A.S. Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothe cin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-kappaB activation. Cancer Research 2000, 60(9):2323-2330. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
20. Czarnecka A.M., Campanella C., Zummo G., Cappello F. Mitochondrial chaperones in cancer: From molecular biology to clinical diagnostics. Cancer Biology & Therapy 2006, 5(7):714-720.
21. Dai Y., Chen S., Kramer L.B., Funk V.L., Dent P., Grant S. Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells. Clinical cancer research: An official journal of the American Association for Cancer Research 2008, 14(2):549-558. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
22. Dai Y., Rahmani M., Dent P., Grant S. Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. Molecular and Cellular Biology 2005, 25(13):5429-5444. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
23. Dasmahapatra G., Lembersky D., Kramer L., Fisher R.I., Friedberg J., Dent P., et al. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood 2010, 115(22):4478-4487. [In Vitro Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
24. Dasmahapatra G., Lembersky D., Son M.P., Attkisson E., Dent P., Fisher R.I., et al. Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo. Molecular Cancer Therapeutics 2011, 10(9):1686-1697. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
25. Daugaard M., Rohde M., Jaattela M. The heat shock protein 70 family: Highly homologous proteins with overlapping and distinct functions. FEBS Letters 2007, 581(19):3702-3710. [Research Support, Non-U.S. Gov't Review].
26. Demo S.D., Kirk C.J., Aujay M.A., Buchholz T.J., Dajee M., Ho M.N., et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Research 2007, 67(13):6383-6391.
27. Deng J., Harding H.P., Raught B., Gingras A.C., Berlanga J.J., Scheuner D., et al. Activation of GCN2 in UV-irradiated cells inhibits translation. Current Biology 2002, 12(15):1279-1286.
28. Deribe Y.L., Wild P., Chandrashaker A., Curak J., Schmidt M.H., Kalaidzidis Y., et al. Regulation of epidermal growth factor receptor trafficking by lysine deacetylase HDAC6. Science Signaling 2009, 2(102):ra84.
29. Eura Y., Yanamoto H., Arai Y., Okuda T., Miyata T., Kokame K. Derlin-1 deficiency is embryonic lethal, Derlin-3 deficiency appears normal, and Herp deficiency is intolerant to glucose load and ischemia in mice. PLoS One 2012, 7(3):e34298. [Research Support, Non-U.S. Gov't].
30. Fels D.R., Koumenis C. The PERK/eIF2alpha/ATF4 module of the UPR in hypoxia resistance and tumor growth. Cancer Biology & Therapy 2006, 5(7):723-728.
31. Franco R.S., Hogg J.W., Martelo O.J. Activation and partial characterization of a human reticulocyte heme-dependent eIF-Z alpha kinase. American Journal of Hematology 1981, 11(1):9-18.
32. Gao Y.S., Hubbert C.C., Yao T.P. The microtubule-associated histone deacetylase 6 (HDAC6) regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation. The Journal of Biological Chemistry 2010, 285(15):11219-11226. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.].
33. Goldberg A.L. Protein degradation and protection against misfolded or damaged proteins. Nature 2003, 426(6968):895-899. [Review].
34. Grant S. Is the focus moving toward a combination of targeted drugs?. Best Practice & Research. Clinical Haematology 2008, 21(4):629-637. [Review].
35. Grant S., Dent P. Simultaneous interruption of signal transduction and cell cycle regulatory pathways: Implications for new approaches to the treatment of childhood leukemias. Current Drug Targets 2007, 8(6):751-759. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Review].
36. Gross M., Olin A., Hessefort S., Bender S. Control of protein synthesis by hemin. Purification of a rabbit reticulocyte hsp 70 and characterization of its regulation of the activation of the hemin-controlled eIF-2(alpha) kinase. The Journal of Biological Chemistry 1994, 269(36):22738-22748.
37. Gross M., Rynning J., Knish W.M. Evidence that the phosphorylation of eukaryotic initiation factor 2 alpha by the hemin-controlled translational repressor occurs at a single site. The Journal of Biological Chemistry 1981, 256(2):589-592.
38. Haggarty S.J., Koeller K.M., Wong J.C., Grozinger C.M., Schreiber S.L. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proceedings of the National Academy of Sciences of the United States of America 2003, 100(8):4389-4394. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.].
39. Hamanaka R.B., Bennett B.S., Cullinan S.B., Diehl J.A. PERK and GCN2 contribute to eIF2alpha phosphorylation and cell cycle arrest after activation of the unfolded protein response pathway. Molecular Biology of the Cell 2005, 16(12):5493-5501.
40. Hara T., Nakamura K., Matsui M., Yamamoto A., Nakahara Y., Suzuki-Migishima R., et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 2006, 441(7095):885-889. [Research Support, Non-U.S. Gov't].
41. Harding H.P., Novoa I., Zhang Y., Zeng H., Wek R., Schapira M., et al. Regulated translation initiation controls stress-induced gene expression in mammalian cells. Molecular Cell 2000, 6(5):1099-1108.
42. Harding H.P., Zhang Y., Bertolotti A., Zeng H., Ron D. Perk is essential for translational regulation and cell survival during the unfolded protein response. Molecular Cell 2000, 5(5):897-904.
43. Harding H.P., Zhang Y., Ron D. Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. Nature 1999, 397(6716):271-274.
44. Harding H.P., Zhang Y., Zeng H., Novoa I., Lu P.D., Calfon M., et al. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Molecular Cell 2003, 11(3):619-633.
45. Hetz C. The unfolded protein response: Controlling cell fate decisions under ER stress and beyond. Nature Reviews. Molecular Cell Biology 2012, 13(2):89-102.
46. Hetz C., Bernasconi P., Fisher J., Lee A.H., Bassik M.C., Antonsson B., et al. Proapoptotic BAX and BAK modulate the unfolded protein response by a direct interaction with IRE1alpha. Science 2006, 312(5773):572-576.
47. Hideshima T., Bradner J.E., Wong J., Chauhan D., Richardson P., Schreiber S.L., et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(24):8567-8572. [Comparative Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
48. Hideshima T., Chauhan D., Richardson P., Mitsiades C., Mitsiades N., Hayashi T., et al. NF-kappa B as a therapeutic target in multiple myeloma. The Journal of Biological Chemistry 2002, 277(19):16639-16647. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
49. Hideshima T., Ikeda H., Chauhan D., Okawa Y., Raje N., Podar K., et al. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 2009, 114(5):1046-1052. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
50. Hightower L.E. Heat shock, stress proteins, chaperones, and proteotoxicity. Cell 1991, 66(2):191-197.
51. Hipp M.S., Patel C.N., Bersuker K., Riley B.E., Kaiser S.E., Shaler T.A., et al. Indirect inhibition of 26S proteasome activity in a cellular model of Huntington's disease. The Journal of Cell Biology 2012, 196(5):573-587. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
52. Hosokawa N., Wada I., Nagasawa K., Moriyama T., Okawa K., Nagata K. Human XTP3-B forms an endoplasmic reticulum quality control scaffold with the HRD1-SEL1L ubiquitin ligase complex and BiP. The Journal of Biological Chemistry 2008, 283(30):20914-20924.
53. Hubbert C., Guardiola A., Shao R., Kawaguchi Y., Ito A., Nixon A., et al. HDAC6 is a microtubule-associated deacetylase. Nature 2002, 417(6887):455-458.
54. Imai Y., Soda M., Hatakeyama S., Akagi T., Hashikawa T., Nakayama K.I., et al. CHIP is associated with Parkin, a gene responsible for familial Parkinson's disease, and enhances its ubiquitin ligase activity. Molecular Cell 2002, 10(1):55-67. [Research Support, Non-U.S. Gov't].
55. Iwata A., Riley B.E., Johnston J.A., Kopito R.R. HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin. The Journal of Biological Chemistry 2005, 280(48):40282-40292. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
56. Jiang H.Y., Wek R.C. Phosphorylation of the alpha-subunit of the eukaryotic initiation factor-2 (eIF2alpha) reduces protein synthesis and enhances apoptosis in response to proteasome inhibition. The Journal of Biological Chemistry 2005, 280(14):14189-14202. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
57. Jona A., Khaskhely N., Buglio D., Shafer J.A., Derenzini E., Bollard C.M., et al. The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors. Experimental Hematology 2011, 39(10):1007-1017. e1001, [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
58. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. The Journal of Clinical Investigation 2009, 119(6):1420-1428. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review].
59. Kamat A.M., Karashima T., Davis D.W., Lashinger L., Bar-Eli M., Millikan R., et al. The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Molecular Cancer Therapeutics 2004, 3(3):279-290. [Research Support, U.S. Gov't, P.H.S.].
60. Kang B.H., Altieri D.C. Compartmentalized cancer drug discovery targeting mitochondrial Hsp90 chaperones. Oncogene 2009, 28(42):3681-3688.
61. Kang B.H., Plescia J., Dohi T., Rosa J., Doxsey S.J., Altieri D.C. Regulation of tumor cell mitochondrial homeostasis by an organelle-specific Hsp90 chaperone network. Cell 2007, 131(2):257-270.
62. Kang B.H., Plescia J., Song H.Y., Meli M., Colombo G., Beebe K., et al. Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. The Journal of Clinical Investigation 2009, 119(3):454-464.
63. Kaser M., Langer T. Protein degradation in mitochondria. Seminars in Cell & Developmental Biology 2000, 11(3):181-190. [Research Support, Non-U.S. Gov't Review].
64. Kawaguchi Y., Kovacs J.J., McLaurin A., Vance J.M., Ito A., Yao T.P. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003, 115(6):727-738.
65. Kikuchi J., Wada T., Shimizu R., Izumi T., Akutsu M., Mitsunaga K., et al. Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. Blood 2010, 116(3):406-417.
66. Kirkin V., Lamark T., Sou Y.S., Bjorkoy G., Nunn J.L., Bruun J.A., et al. A role for NBR1 in autophagosomal degradation of ubiquitinated substrates. Molecular Cell 2009, 33(4):505-516. [Research Support, Non-U.S. Gov't].
67. Kirkin V., McEwan D.G., Novak I., Dikic I. A role for ubiquitin in selective autophagy. Molecular Cell 2009, 34(3):259-269. [Research Support, Non-U.S. Gov't Review].
68. Klionsky D.J. Neurodegeneration: Good riddance to bad rubbish. Nature 2006, 441(7095):819-820. [Comment News].
69. Klionsky D.J., Abeliovich H., Agostinis P., Agrawal D.K., Aliev G., Askew D.S., et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 2008, 4(2):151-175. [Research Support, N.I.H., Extramural Review].
70. Komatsu M., Waguri S., Chiba T., Murata S., Iwata J., Tanida I., et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 2006, 441(7095):880-884. [Research Support, Non-U.S. Gov't].
71. Kopito R.R. Aggresomes, inclusion bodies and protein aggregation. Trends in Cell Biology 2000, 10(12):524-530.
72. Koritzinsky M., Magagnin M.G., van den Beucken T., Seigneuric R., Savelkouls K., Dostie J., et al. Gene expression during acute and prolonged hypoxia is regulated by distinct mechanisms of translational control. The EMBO Journal 2006, 25(5):1114-1125.
73. Koumenis C., Naczki C., Koritzinsky M., Rastani S., Diehl A., Sonenberg N., et al. Regulation of protein synthesis by hypoxia via activation of the endoplasmic reticulum kinase PERK and phosphorylation of the translation initiation factor eIF2alpha. Molecular and Cellular Biology 2002, 22(21):7405-7416.
74. Kramer G., Henderson A.B., Pinphanichakarn P., Wallis M.H., Hardesty B. Partial reaction of peptide initiation inhibited by phosphorylation of either initiation factor eIF-2 or 40S ribosomal proteins. Proceedings of the National Academy of Sciences of the United States of America 1977, 74(4):1445-1449.
75. Lafarga V., Aymerich I., Tapia O., Mayor F., Penela P. A novel GRK2/HDAC6 interaction modulates cell spreading and motility. The EMBO Journal 2012, 31(4):856-869. [Research Support, Non-U.S. Gov't].
76. Lashinger L.M., Zhu K., Williams S.A., Shrader M., Dinney C.P., McConkey D.J. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. Cancer Research 2005, 65(11):4902-4908. [Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.].
77. Lee A.S., Hendershot L.M. ER stress and cancer. Cancer Biology & Therapy 2006, 5(7):721-722.
78. Lee J.Y., Koga H., Kawaguchi Y., Tang W., Wong E., Gao Y.S., et al. HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy. The EMBO Journal 2010, 29(5):969-980.
79. Liu L., Cash T.P., Jones R.G., Keith B., Thompson C.B., Simon M.C. Hypoxia-induced energy stress regulates mRNA translation and cell growth. Molecular Cell 2006, 21(4):521-531.
80. Loktev A.V., Zhang Q., Beck J.S., Searby C.C., Scheetz T.E., Bazan J.F., et al. A BBSome subunit links ciliogenesis, microtubule stability, and acetylation. Developmental Cell 2008, 15(6):854-865. [Research Support, N.I.H., Extramural].
81. Lu L., Han A.P., Chen J.J. Translation initiation control by heme-regulated eukaryotic initiation factor 2alpha kinase in erythroid cells under cytoplasmic stresses. Molecular and Cellular Biology 2001, 21(23):7971-7980.
82. Matthias P., Yoshida M., Khochbin S. HDAC6 a new cellular stress surveillance factor. Cell Cycle 2008, 7(1):7-10. [Research Support, Non-U.S. Gov't Review].
83. McConkey D. Proteasome and HDAC: Who's zooming who?. Blood 2010, 116(3):308-309.
84. McConkey D.J., Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug resistance updates: Reviews and commentaries in antimicrobial and anticancer chemotherapy 2008, 11(4-5):164-179. [Review].
85. McDonough H., Patterson C. CHIP: A link between the chaperone and proteasome systems. Cell Stress & Chaperones 2003, 8(4):303-308. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Review].
86. McEwen E., Kedersha N., Song B., Scheuner D., Gilks N., Han A., et al. Heme-regulated inhibitor kinase-mediated phosphorylation of eukaryotic translation initiation factor 2 inhibits translation, induces stress granule formation, and mediates survival upon arsenite exposure. The Journal of Biological Chemistry 2005, 280(17):16925-16933.
87. Meister S., Schubert U., Neubert K., Herrmann K., Burger R., Gramatzki M., et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Research 2007, 67(4):1783-1792. [Research Support, Non-U.S. Gov't].
88. Mellor H., Flowers K.M., Kimball S.R., Jefferson L.S. Cloning and characterization of cDNA encoding rat hemin-sensitive initiation factor-2 alpha (eIF-2 alpha) kinase. Evidence for multitissue expression. The Journal of Biological Chemistry 1994, 269(14):10201-10204.
89. Meurs E., Chong K., Galabru J., Thomas N.S., Kerr I.M., Williams B.R., et al. Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon. Cell 1990, 62(2):379-390.
90. Michaud E.J., Yoder B.K. The primary cilium in cell signaling and cancer. Cancer Research 2006, 66(13):6463-6467. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Review].
91. Miller C.P., Ban K., Dujka M.E., McConkey D.J., Munsell M., Palladino M., et al. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood 2007, 110(1):267-277. [Research Support, N.I.H., Extramural].
92. Mirault M.E., Southgate R., Delwart E. Regulation of heat-shock genes: A DNA sequence upstream of Drosophila hsp70 genes is essential for their induction in monkey cells. The EMBO Journal 1982, 1:1279-1285.
93. Mitsiades C.S., Mitsiades N.S., McMullan C.J., Poulaki V., Kung A.L., Davies F.E., et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood 2006, 107:1092-1100.
94. Mizushima N., Levine B., Cuervo A.M., Klionsky D.J. Autophagy fights disease through cellular self-digestion. Nature 2008, 451(7182):1069-1075. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review].
95. Modi S., Stopeck A., Linden H., Solit D., Chandarlapaty S., Rosen N., et al. HSP90 inhibition is effective in breast cancer: A phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clinical Cancer Research 2011, 17:5132-5139.
96. Moreau P., Richardson P.G., Cavo M., Orlowski R.Z., San Miguel J.F., Palumbo A., et al. Proteasome inhibitors in multiple myeloma: Ten years later. Blood 2012, 120(5):947-959.
97. Morimoto R.I. Cells in stress: Transcriptional activation of heat shock genes. Science 1993, 259(5100):1409-1410.
98. Morimoto R.I. The heat shock response: Systems biology of proteotoxic stress in aging and disease. Cold Spring Harbor Symposia on Quantitative Biology 2011, 76:91-99.
99. Murata S., Chiba T., Tanaka K. CHIP: A quality-control E3 ligase collaborating with molecular chaperones. The International Journal of Biochemistry & Cell Biology 2003, 35(5):572-578. [Review].
100. Naranmandura H., Xu S., Koike S., Pan L.Q., Chen B., Wang Y.W., et al. The endoplasmic reticulum is a target organelle for trivalent dimethylarsinic acid (DMAIII)-induced cytotoxicity. Toxicology and Applied Pharmacology 2012, 260:241-249.
101. Nawrocki S.T., Bruns C.J., Harbison M.T., Bold R.J., Gotsch B.S., Abbruzzese J.L., et al. Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Molecular Cancer Therapeutics 2002, 1(14):1243-1253.
102. Nawrocki S.T., Carew J.S., Dunner K., Boise L.H., Chiao P.J., Huang P., et al. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Research 2005, 65(24):11510-11519. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
103. Nawrocki S.T., Carew J.S., Maclean K.H., Courage J.F., Huang P., Houghton J.A., et al. Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA. Blood 2008, 112(7):2917-2926. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
104. Nawrocki S.T., Carew J.S., Pino M.S., Highshaw R.A., Andtbacka R.H., Dunner K., et al. Aggresome disruption: A novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Research 2006, 66(7):3773-3781. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
105. Nawrocki S.T., Carew J.S., Pino M.S., Highshaw R.A., Dunner K., Huang P., et al. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Research 2005, 65(24):11658-11666.
106. Nebbioso A., Clarke N., Voltz E., Germain E., Ambrosino C., Bontempo P., et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nature Medicine 2005, 11(1):77-84. [Research Support, Non-U.S. Gov't].
107. Nishitoh H., Matsuzawa A., Tobiume K., Saegusa K., Takeda K., Inoue K., et al. ASK1 is essential for endoplasmic reticulum stress-induced neuronal cell death triggered by expanded polyglutamine repeats. Genes & Development 2002, 16(11):1345-1355.
108. Obeng E.A., Carlson L.M., Gutman D.M., Harrington W.J., Lee K.P., Boise L.H. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006, 107(12):4907-4916. [Comparative Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
109. Oda Y., Okada T., Yoshida H., Kaufman R.J., Nagata K., Mori K. Derlin-2 and Derlin-3 are regulated by the mammalian unfolded protein response and are required for ER-associated degradation. The Journal of Cell Biology 2006, 172(3):383-393. [Research Support, Non-U.S. Gov't].
110. Pandey U.B., Nie Z., Batlevi Y., McCray B.A., Ritson G.P., Nedelsky N.B., et al. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 2007, 447(7146):859-863.
111. Parato K.A., Senger D., Forsyth P.A., Bell J.C. Recent progress in the battle between oncolytic viruses and tumours. Nature Reviews. Cancer 2005, 5:965-976.
112. Pei X.Y., Dai Y., Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clinical cancer research: An official journal of the American Association for Cancer Research 2004, 10(11):3839-3852. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.].
113. Penela P., Lafarga V., Tapia O., Rivas V., Nogues L., Lucas E., et al. Roles of GRK2 in cell signaling beyond GPCR desensitization: GRK2-HDAC6 interaction modulates cell spreading and motility. Science Signaling 2012, 5(224):pt3.
114. Petroski M.D., Deshaies R.J. Function and regulation of cullin-RING ubiquitin ligases. Nature Reviews. Molecular Cell Biology 2005, 6(1):9-20. [Research Support, Non-U.S. Gov't Review].
115. Potts B.C., Albitar M.X., Anderson K.C., Baritaki S., Berkers C., Bonavida B., et al. Marizomib, a proteasome inhibitor for all seasons: Preclinical profile and a framework for clinical trials. Current Cancer Drug Targets 2011, 11(3):254-284. [Research Support, N.I.H., Extramural Review].
116. Quinlan R.J., Tobin J.L., Beales P.L. Modeling ciliopathies: Primary cilia in development and disease. Current Topics in Developmental Biology 2008, 84:249-310. [Review].
117. Ramirez M., Wek R.C., Hinnebusch A.G. Ribosome association of GCN2 protein kinase, a translational activator of the GCN4 gene of Saccharomyces cerevisiae. Molecular and Cellular Biology 1991, 11(6):3027-3036.
118. Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. The New England Journal of Medicine 2003, 348(26):2609-2617. [Clinical Trial Clinical Trial, Phase II Multicenter Study Research Support, Non-U.S. Gov't].
119. Ron D., Hubbard S.R. How IRE1 reacts to ER stress. Cell 2008, 132(1):24-26.
120. Ron D., Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nature Reviews. Molecular Cell Biology 2007, 8(7):519-529.
121. Roussos E.T., Keckesova Z., Haley J.D., Epstein D.M., Weinberg R.A., Condeelis J.S. AACR special conference on epithelial-mesenchymal transition and cancer progression and treatment. Cancer Research 2010, 70(19):7360-7364. [Congresses].
122. Ruschak A.M., Slassi M., Kay L.E., Schimmer A.D. Novel proteasome inhibitors to overcome bortezomib resistance. Journal of the National Cancer Institute 2011, 103(13):1007-1017. [Research Support, Non-U.S. Gov't Review].
123. Santo L., Hideshima T., Kung A.L., Tseng J.C., Tamang D., Yang M., et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 2012, 119(11):2579-2589.
124. Sayers T.J., Brooks A.D., Koh C.Y., Ma W., Seki N., Raziuddin A., et al. The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 2003, 102(1):303-310. [Research Support, U.S. Gov't, P.H.S.].
125. Shan B., Yao T.P., Nguyen H.T., Zhuo Y., Levy D.R., Klingsberg R.C., et al. Requirement of HDAC6 for transforming growth factor-beta1-induced epithelial-mesenchymal transition. The Journal of Biological Chemistry 2008, 283(30):21065-21073. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
126. Shi Y., Mosser D.D., Morimoto R.I. Molecular chaperones as HSF1-specific transcriptional repressors. Genes & Development 1998, 12(5):654-666. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
127. Shi Y., Vattem K.M., Sood R., An J., Liang J., Stramm L., et al. Identification and characterization of pancreatic eukaryotic initiation factor 2 alpha-subunit kinase, PEK, involved in translational control. Molecular and Cellular Biology 1998, 18(12):7499-7509.
128. Siegelin M.D., Dohi T., Raskett C.M., Orlowski G.M., Powers C.M., Gilbert C.A., et al. Exploiting the mitochondrial unfolded protein response for cancer therapy in mice and human cells. The Journal of Clinical Investigation 2011, 121(4):1349-1360.
129. Simpson F., Kerr M.C., Wicking C. Trafficking, development and hedgehog. Mechanisms of Development 2009, 126(5-6):279-288. [Review].
130. Smith D.M., Benaroudj N., Goldberg A. Proteasomes and their associated ATPases: A destructive combination. Journal of Structural Biology 2006, 156(1):72-83. [Review].
131. Smith D.M., Chang S.C., Park S., Finley D., Cheng Y., Goldberg A.L. Docking of the proteasomal ATPases' carboxyl termini in the 20S proteasome's alpha ring opens the gate for substrate entry. Molecular Cell 2007, 27(5):731-744. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
132. Smith D.M., Fraga H., Reis C., Kafri G., Goldberg A.L. ATP binds to proteasomal ATPases in pairs with distinct functional effects, implying an ordered reaction cycle. Cell 2011, 144(4):526-538. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
133. Smith M.H., Ploegh H.L., Weissman J.S. Road to ruin: Targeting proteins for degradation in the endoplasmic reticulum. Science 2011, 334(6059):1086-1090. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review].
134. Solit D.B., Zheng F.F., Drobnjak M., Munster P.N., Higgins B., Verbel D., et al. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clinical Cancer Research 2002, 8:986-993.
135. Sood R., Porter A.C., Olsen D.A., Cavener D.R., Wek R.C. A mammalian homologue of GCN2 protein kinase important for translational control by phosphorylation of eukaryotic initiation factor-2alpha. Genetics 2000, 154(2):787-801.
136. Stojdl D.F., Lichty B., Knowles S., Marius R., Atkins H., Sonenberg N., et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nature Medicine 2000, 6:821-825.
137. Sunwoo J.B., Chen Z., Dong G., Yeh N., Crowl Bancroft C., Sausville E., et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clinical cancer research: An official journal of the American Association for Cancer Research 2001, 7(5):1419-1428. [Research Support, U.S. Gov't, P.H.S.].
138. Szegezdi E., Lobgue S.E., Gorman A.M., Samali A. Mediators of endoplasmic stress-induced apoptosis. EMBO Reports 2006, 7:880-885.
139. Tabas I., Ron D. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nature Cell Biology 2011, 13(3):184-190.
140. Talloczy Z., Jiang W., Virgin H.W., Leib D.A., Scheuner D., Kaufman R.J., et al. Regulation of starvation- and virus-induced autophagy by the eIF2alpha kinase signaling pathway. Proceedings of the National Academy of Sciences of the United States of America 2002, 99(1):190-195.
141. Thibault G., Ismail N., Ng D.T. The unfolded protein response supports cellular robustness as a broad-spectrum compensatory pathway. Proceedings of the National Academy of Sciences of the United States of America 2011, 108(51):20597-20602. [Research Support, Non-U.S. Gov't].
142. Tully D.B., Collins B.J., Overstreet J.D., Smith C.S., Dinse G.E., Mumtaz M.M., et al. Effects of arsenic, cadmium, chromium, and lead on gene expression regulated by a battery of 13 different promoters in recombinant HepG2 cells. Toxicology and Applied Pharmacology 2000, 168:79-90.
143. Vabulas R.M., Hartl F.U. Protein synthesis upon acute nutrient restriction relies on proteasome function. Science 2005, 310(5756):1960-1963. [Research Support, Non-U.S. Gov't].
144. Valenzuela-Fernandez A., Cabrero J.R., Serrador J.M., Sanchez-Madrid F. HDAC6: A key regulator of cytoskeleton, cell migration and cell-cell interactions. Trends in Cell Biology 2008, 18(6):291-297. [Research Support, Non-U.S. Gov't Review].
145. Walter P., Ron D. The unfolded protein response: From stress pathway to homeostatic regulation. Science 2011, 334(6059):1081-1086.
146. Webster T.J., Naylor D.J., Hartman D.J., Hoj P.B., Hoogenraad N.J. cDNA cloning and efficient mitochondrial import of pre-mtHSP70 from rat liver. DNA and Cell Biology 1994, 13(12):1213-1220.
147. Wehner K.A., Schutz S., Sarnow P. OGFOD1, a novel modulator of eukaryotic translation initiation factor 2alpha phosphorylation and the cellular response to stress. Molecular and Cellular Biology 2010, 30(8):2006-2016.
148. Wek R.C., Cavener D.R. Translational control and the unfolded protein response. Antioxidants & Redox Signaling 2007, 9(12):2357-2371.
149. Wek R.C., Jackson B.M., Hinnebusch A.G. Juxtaposition of domains homologous to protein kinases and histidyl-tRNA synthetases in GCN2 protein suggests a mechanism for coupling GCN4 expression to amino acid availability. Proceedings of the National Academy of Sciences of the United States of America 1989, 86(12):4579-4583.
150. Wek S.A., Zhu S., Wek R.C. The histidyl-tRNA synthetase-related sequence in the eIF-2 alpha protein kinase GCN2 interacts with tRNA and is required for activation in response to starvation for different amino acids. Molecular and Cellular Biology 1995, 15(8):4497-4506.
151. Westerheide S.D., Morimoto R.I. Heat shock response modulators as therapeutic tools for diseases of protein conformation. The Journal of Biological Chemistry 2005, 280(39):33097-33100.
152. Witta S.E., Gemmill R.M., Hirsch F.R., Coldren C.D., Hedman K., Ravdel L., et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Research 2006, 66(2):944-950. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
153. Workman P., Burrows F., Neckers L., Rosen N. Drugging the cancer chaperone HSP90: Combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Annals of the New York Academy of Sciences 2007, 1113:202-216.
154. Wouters B.G., van den Beucken T., Magagnin M.G., Koritzinsky M., Fels D., Koumenis C. Control of the hypoxic response through regulation of mRNA translation. Seminars in Cell & Developmental Biology 2005, 16(4-5):487-501.
155. Wu Y.C., Yen W.Y., Lee T.C., Yih L.H. Heat shock protein inhibitors, 17-DMAG and KNK437, enhance arsenic trioxide-induced mitotic apoptosis. Toxicology and Applied Pharmacology 2009, 236:231-238.
156. Xu W., Trepel J., Neckers L. Ras, ROS and proteotoxic stress: A delicate balance. Cancer Cell 2011, 20(3):281-282.
157. Yoshida H., Matsui T., Yamamoto A., Okada T., Mori K. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell 2001, 107(7):881-891.
158. Zhan K., Vattem K.M., Bauer B.N., Dever T.E., Chen J.J., Wek R.C. Phosphorylation of eukaryotic initiation factor 2 by heme-regulated inhibitor kinase-related protein kinases in Schizosaccharomyces pombe is important for fesistance to environmental stresses. Molecular and Cellular Biology 2002, 22(20):7134-7146.
159. Zhang Y., Li N., Caron C., Matthias G., Hess D., Khochbin S., et al. HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. The EMBO Journal 2003, 22(5):1168-1179.
160. Zhu K., Chan W., Heymach J., Wilkinson M., McConkey D.J. Control of HIF-1alpha expression by eIF2 alpha phosphorylation-mediated translational repression. Cancer Research 2009, 69(5):1836-1843.
161. Zhu K., Dunner K., McConkey D.J. Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells. Oncogene 2010, 29(3):451-462.